Exagen Statistics
Total Valuation
Exagen has a market cap or net worth of $74.56 million. The enterprise value is $67.08 million.
Important Dates
The next confirmed earnings date is Tuesday, March 10, 2026, before market open.
| Earnings Date | Mar 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Exagen has 22.66 million shares outstanding. The number of shares has increased by 12.25% in one year.
| Current Share Class | 22.66M |
| Shares Outstanding | 22.66M |
| Shares Change (YoY) | +12.25% |
| Shares Change (QoQ) | +8.80% |
| Owned by Insiders (%) | 15.69% |
| Owned by Institutions (%) | 51.58% |
| Float | 14.53M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.17 |
| Forward PS | 1.02 |
| PB Ratio | 4.08 |
| P/TBV Ratio | 4.11 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.05 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.08, with a Debt / Equity ratio of 1.55.
| Current Ratio | 4.08 |
| Quick Ratio | 3.63 |
| Debt / Equity | 1.55 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.51 |
Financial Efficiency
Return on equity (ROE) is -122.81% and return on invested capital (ROIC) is -18.81%.
| Return on Equity (ROE) | -122.81% |
| Return on Assets (ROA) | -14.66% |
| Return on Invested Capital (ROIC) | -18.81% |
| Return on Capital Employed (ROCE) | -24.99% |
| Weighted Average Cost of Capital (WACC) | 13.43% |
| Revenue Per Employee | $295,809 |
| Profits Per Employee | -$88,553 |
| Employee Count | 215 |
| Asset Turnover | 1.20 |
| Inventory Turnover | 7.90 |
Taxes
In the past 12 months, Exagen has paid $50,000 in taxes.
| Income Tax | 50,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +3.14% in the last 52 weeks. The beta is 1.91, so Exagen's price volatility has been higher than the market average.
| Beta (5Y) | 1.91 |
| 52-Week Price Change | +3.14% |
| 50-Day Moving Average | 4.44 |
| 200-Day Moving Average | 7.65 |
| Relative Strength Index (RSI) | 36.01 |
| Average Volume (20 Days) | 342,233 |
Short Selling Information
The latest short interest is 885,707, so 3.91% of the outstanding shares have been sold short.
| Short Interest | 885,707 |
| Short Previous Month | 586,232 |
| Short % of Shares Out | 3.91% |
| Short % of Float | 6.10% |
| Short Ratio (days to cover) | 1.30 |
Income Statement
In the last 12 months, Exagen had revenue of $63.60 million and -$19.04 million in losses. Loss per share was -$0.94.
| Revenue | 63.60M |
| Gross Profit | 38.07M |
| Operating Income | -12.48M |
| Pretax Income | -18.99M |
| Net Income | -19.04M |
| EBITDA | -10.55M |
| EBIT | -12.48M |
| Loss Per Share | -$0.94 |
Full Income StatementBalance Sheet
The company has $35.65 million in cash and $28.17 million in debt, with a net cash position of $7.49 million or $0.33 per share.
| Cash & Cash Equivalents | 35.65M |
| Total Debt | 28.17M |
| Net Cash | 7.49M |
| Net Cash Per Share | $0.33 |
| Equity (Book Value) | 18.14M |
| Book Value Per Share | 0.81 |
| Working Capital | 39.70M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$10.25 million and capital expenditures -$743,000, giving a free cash flow of -$10.99 million.
| Operating Cash Flow | -10.25M |
| Capital Expenditures | -743,000 |
| Free Cash Flow | -10.99M |
| FCF Per Share | -$0.49 |
Full Cash Flow StatementMargins
Gross margin is 59.86%, with operating and profit margins of -19.62% and -29.94%.
| Gross Margin | 59.86% |
| Operating Margin | -19.62% |
| Pretax Margin | -29.86% |
| Profit Margin | -29.94% |
| EBITDA Margin | -16.58% |
| EBIT Margin | -19.62% |
| FCF Margin | n/a |
Dividends & Yields
Exagen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.25% |
| Shareholder Yield | -12.25% |
| Earnings Yield | -25.53% |
| FCF Yield | -14.74% |
Analyst Forecast
The average price target for Exagen is $11.00, which is 234.35% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $11.00 |
| Price Target Difference | 234.35% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 11.98% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Exagen has an Altman Z-Score of -4.27 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.27 |
| Piotroski F-Score | 4 |
